SCHEMBL19612062

SCHEMBL19612062

Cc1cccc2c1CN([C@@H]1CCCCNC1=O)C2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.48
HTR2C P28335 2/20 0.48
HTR2B P41595 2/20 0.48
CRBN Q96SW2 7/20 0.47
IKZF3 Q9UKT9 2/20 0.46
DDB1 Q16531 2/20 0.46
IKZF1 Q13422 2/20 0.46
BRD4 O60885 1/20 0.46
TNF P01375 1/20 0.46
IL1B P01584 1/20 0.46
MAP1LC3B Q9GZQ8 3/20 0.41
PARP1 P09874 1/20 0.40
PARP10 Q53GL7 1/20 0.40
PARP11 Q9NR21 1/20 0.40
IKZF2 Q9UKS7 1/20 0.38
ACHE P22303 1/20 0.38
GSPT1 P15170 1/20 0.37
CDK5 Q00535 1/20 0.37
DYRK1A Q13627 1/20 0.37
CDK5R1 Q15078 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18270984 1.00 HTR2A (0.48) HTR2AHTR2CHTR2BCRBNIKZF3
SCHEMBL19612063 1.00 HTR2A (0.48) HTR2AHTR2CHTR2BCRBNIKZF3
SCHEMBL20766653 0.86 CRBN (0.64) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL20766651 0.86 CRBN (0.64) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL19611979 0.85 HTR2A (0.50) HTR2AHTR2CHTR2BCRBNIKZF3
SCHEMBL19611980 0.85 HTR2A (0.50) HTR2AHTR2CHTR2BCRBNIKZF3
SCHEMBL19611910 0.85 MAPK1 (0.53) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL19611971 0.85 CRBN (0.50) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL19611961 0.85 CRBN (0.47) HTR2AHTR2CHTR2BCRBNIKZF3
SCHEMBL19611973 0.85 CRBN (0.50) CRBNIKZF3DDB1IKZF1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-02-18 US disclosed
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-09-12 US disclosed
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-12-04 US disclosed
US-9938302-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-04-10 US disclosed
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
WO-2017201069-A1 OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS BIOTHERYX, INC. (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B HTR2A 4256/4885HTR2C 3907/4885HTR2B 3995/4885
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B HTR2A 4256/4885HTR2C 3907/4885HTR2B 3995/4885
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B HTR2A 4256/4885HTR2C 3907/4885HTR2B 3995/4885
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B HTR2A 4256/4885HTR2C 3907/4885HTR2B 3995/4885
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B HTR2A 4256/4885HTR2C 3907/4885HTR2B 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.